Cyramza and Bacteremic shock - a phase IV clinical study of FDA data

Summary:

Bacteremic shock is reported as a side effect among people who take Cyramza (ramucirumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Abraxane, and have Gastric cancer.

The phase IV clinical study analyzes which people have Bacteremic shock when taking Cyramza. It is created by eHealthMe based on reports of 4,051 people who have side effects when taking Cyramza from the FDA, and is updated regularly.

What is Cyramza?

Cyramza has active ingredients of ramucirumab. eHealthMe is studying from 4,052 Cyramza users. Check the latest studies of Cyramza.

What is Bacteremic shock?

Bacteremic shock (septic shock caused by the release of toxins by bacteria) is found to be associated with 2,191 drugs and 3,397 conditions by eHealthMe. Check the latest studies of Bacteremic shock.

On Jun, 24, 2026

4,051 people reported to have side effects when taking Cyramza.
Among them, 48 people (1.18%) have Bacteremic shock.

Among these 48 people:

How long have people been on Cyramza when they have Bacteremic shock? *

What is the gender of people who have Bacteremic shock when taking Cyramza? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Bacteremic shock when taking Cyramza? *

What are other drugs people take besides Cyramza? *

Abraxane: 7 people, 14.58%
Amlodipine: 4 people, 8.33%
Decadron: 3 people, 6.25%
Dexamethasone Sodium Phosphate: 3 people, 6.25%
Fluorouracil: 3 people, 6.25%
Polaramine: 3 people, 6.25%
Levoleucovorin Calcium: 3 people, 6.25%
Paclitaxel: 3 people, 6.25%
Nexium: 2 people, 4.17%
Buscopan: 2 people, 4.17%

What are other side effects people have besides Bacteremic shock? *

Febrile Neutropenia (fever with reduced white blood cells): 18 people, 37.50%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 14 people, 29.17%
Malignant Neoplasm Progression (cancer tumour came back): 6 people, 12.50%
Bone Marrow Failure: 5 people, 10.42%
Diarrhea: 5 people, 10.42%
Gastrointestinal Perforation (hole in the digestive tract): 5 people, 10.42%
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 5 people, 10.42%
Pneumonia: 5 people, 10.42%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 10.42%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 4 people, 8.33%

What are the existing conditions these people have? *

Gastric Cancer (stomach cancer): 16 people, 33.33%
High Blood Pressure: 4 people, 8.33%
Gastric Cancer Recurrent (repeat stomach cancer): 4 people, 8.33%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 4 people, 8.33%
Allergies: 3 people, 6.25%
Oedema (fluid collection in tissue): 3 people, 6.25%
Gastric Cancer Stage Iv (cancer cells have spread to distant organs): 3 people, 6.25%
Stomatitis (inflammation of mucous membrane of mouth): 2 people, 4.17%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 4.17%
Dry Skin: 2 people, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Cyramza and have Bacteremic shock?

- Check whether Bacteremic shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyramza:

Cyramza (4,052 reports)

Bacteremic shock treatments and more:

Bacteremic shock (51,128 reports)

Browse all side effects of Cyramza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bacteremic shock:

Bacteremic shock (2,191 drugs)

Browse all the conditions that are associated with Bacteremic shock:

Bacteremic shock (3,397 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramucirumab (the active ingredients of Cyramza) and Cyramza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.